In a report published Tuesday, Morgan Stanley analyst Bin Li reiterated an Equal-Weight rating on Mindray Medical International Ltd. MR, but removed the $37.00 price target.
In the report, Morgan Stanley noted, “MR reported in-line 1Q14 sales growth on continued weak China business but stabilized ex-China growth, while non-GAAP profit was also in line. Notably, operating income was 13% below our estimate, but helped by the lower tax rate. Given the challenging China environment and the departure of the COO, Mr. Liu Jie, who has been instrumental to Mindray's healthy growth in the past few years, we do not expect improving profit growth in the near term.”
Mindray Medical International Ltd. closed on Monday at $33.67.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in